Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. nonprovisional application claiming priority to the May 2021 PCT application. The company noted that the International Patent Searching authority had written an opinion supporting novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing, including claims to compositions and methods that support elements of the company’s preclinical and research programs. In addition Cybin shareholders elected a new member to its board of directors during the company’s Aug. 6, 2021, annual and special meeting of shareholders. Theresa Firestone, a senior healthcare executive with an impressive background in retail, pharmaceutical, health and wellness, government and global restructuring, will be Cybin’s newest board member. The company also noted the results for other items voted on during the meeting, which had 53 shareholders in attendance in person or by proxy. Regarding the patent application, Cybin CEO Doug Drysdale stated the following in the press release: “Cybin’s portfolio now consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies, 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy resistant psychiatric disorders. We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our preclinical findings thus expanding and strengthening IP.”
To view the full press releases, visit https://ibn.fm/7WoZG and https://ibn.fm/y0qcf
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
